º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Manufacturing

Smith & Nephew raises full-year sales target as strong 2019 continues

The FTSE 100 manufacturer, based in Hull, saw its first-half sales boosted by strong performance in China

Smith & Nephew is a FTSE-listed medical manufacturer based in Hull(Image: Mail News & Media Ltd.)

Medical giant Smith & Nephew raised its full-year revenue growth targets for a second time in three months as its strong start to 2019 continued.

The FTSE 100 firm, headquartered in Hull, saw sales in the first half of the year rise almost two per cent on the same period in 2018, as operating profits also surged.

Smith & Nephew said strong performance in China had contributed to the rise, as its sales in the Far East country soared by more than 30 per cent.

Namal Nawana, CEO at Smith & Nephew, said: "The positive momentum across the business globally in the first half of 2019 has led us to upgrade our full year revenue growth guidance.

"Organic revenue growth has been solid across all three franchises, with strong performance in Emerging Markets and global Sports Medicine. At the same time, we expanded our margin.

"We are delivering on our commitments to accelerate revenue growth, improve profitability and importantly make investments that support the long-term success of Smith & Nephew."

Smith and Nephew CEO, Namal Nawana(Image: Hull Daily Mail)

Sales at Smith & Nephew hit $2.49bn in the first half of 2019 – up from $2.44bn in the same period last year

Operating profits rose to $419m, boosted by a string of impressive acquisitions from Smith & Nephew in 2019.